These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 33800517)
1. PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties. Garnuszek P; Karczmarczyk U; Maurin M; Sikora A; Zaborniak J; Pijarowska-Kruszyna J; Jaroń A; Wyczółkowska M; Wojdowska W; Pawlak D; Lipiński PFJ; Mikołajczak R Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800517 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Umbricht CA; Benešová M; Schibli R; Müller C Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274 [TBL] [Abstract][Full Text] [Related]
3. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Benešová M; Umbricht CA; Schibli R; Müller C Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Multidose Preparation of a Ready-to-Use Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687 [No Abstract] [Full Text] [Related]
5. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127 [TBL] [Abstract][Full Text] [Related]
6. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841 [TBL] [Abstract][Full Text] [Related]
9. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting. Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611 [TBL] [Abstract][Full Text] [Related]
10. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake. Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623 [TBL] [Abstract][Full Text] [Related]
11. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Kelly J; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Schlyer D; Zhao Y; Kim D; Babich JW Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1841-1851. PubMed ID: 29623376 [TBL] [Abstract][Full Text] [Related]
12. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related]
13. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344 [TBL] [Abstract][Full Text] [Related]
14. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629 [TBL] [Abstract][Full Text] [Related]